Table 3.
Distribution of ESBL- and MBL-producing isolates among MDR Pseudomonas aeruginosa isolates from different clinical specimens
| Type of infection | MDR P. aeruginosa | ESBLs | MBL | ||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Wound | 59 | 24 | 40% | 4 | 19% |
| Ear | 20 | 16 | 80% | 3 | 14.3% |
| Burns | 2 | 1 | 50% | — | — |
| Urinary tract | 2 | 1 | 50% | — | — |
| Chest | 4 | 3 | 75% | 1 | 4.8% |
| Gastroenteritis | 3 | 2 | 66.7% | 1 | 4.8% |
| Patients admitted to ICU (from buccal cavity, skin swab, and eye swab) | 10 | 7 | 70% | 2 | 9.5% |
| Total | 100 | 54 | 54% | 11 | 11% |
Note: Percentages correlated with number of MDR P. aeruginosa isolates from each type of infection.
Abbreviations: ICU, intensive-care unit; MDR, multidrug-resistant; ESBL, extended-spectrum β-lactamase; MBL, metallo-β-lactamase.